CoV enters into the host cell via transmembrane spike (S) made up of glycoproteins which helps in forming homotrimers protruding from its surfaces (Tortorici & Veesler, 2019). S is comprised of two functional subunits (S1 and S2) which permit its efficient binding to the host cell surface receptor and also, helps in viral and cellular membranes fusion (Burkard et al., 2014; Kirchdoerfer et al., 2018; Millet & Whittaker, 2014). ACE2 (Angiotensin converting enzyme 2) has been reported to be a central component mediating the viral entry into the host cell. ACE2 is expressed in gastrointestinal tract, endocrine tissues, kidneys, liver/gall bladder, testis and to smaller extents in lungs. The Receptor Binding Domain of spike proteins induces conformational changes in ACE2 receptors, which further dissociates the S1 subunit of the spike and hence initiates host cell membrane fusion. Therefore, ACE2 might play a vital role in drug designing. Amidst all these few names came into the picture mainly hydroxychloroquine, arbidol, remdesivir, and favipiravir etc. these drugs are taken as potential candidates according to National Health Commission (NHC) of the People’s Republic of China. But none proved to be successful in severe respiratory distress or each one works differently according to an individual’s immune system.